Avidity Biosciences (Nasdaq:RNA) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

RNA Aperçu des actions

Avidity Biosciences, Inc. est une société biopharmaceutique qui se consacre à l'administration de thérapies à base d'ARN.

A propos de l'entreprise

RNA analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	2/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Se négocie à 63.6% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 69.89% par an

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Ventes d'initiés importantes au cours des 3 derniers mois

Avidity Biosciences, Inc. Concurrents

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$5.4b

Immunovant

NasdaqGS:IMVT

US$4.3b

IVERIC bio

NasdaqGS:ISEE

US$5.5b

Denali Therapeutics

NasdaqGS:DNLI

US$4.4b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Avidity Biosciences
Historique des cours de bourse
Prix actuel de l'action	US$41.75
Plus haut sur 52 semaines	US$48.80
Plus bas sur 52 semaines	US$4.83
Bêta	0.89
1Variation sur 1 mois	-7.18%
Variation sur 3 mois	8.92%
Variation sur 1 an	499.86%
3Variation sur 3 ans	75.72%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	46.49%

Nouvelles et mises à jour récentes

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11

Recent updates

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30

Rendement pour les actionnaires

	RNA	US Biotechs	US Marché
7D	2.4%	3.5%	3.0%
1Y	499.9%	21.0%	24.6%

Rendement vs Industrie: RNA a dépassé le secteur US Biotechs qui a rapporté 14.9 % au cours de l'année écoulée.

Rendement vs marché: RNA a dépassé le marché US qui a rapporté 25.4 % au cours de l'année écoulée.

Volatilité des prix

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	7.9%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de RNA a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de RNA ( 8% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2012	253	Sarah Boyce	www.aviditybiosciences.com

Avidity Biosciences, Inc. est une société biopharmaceutique qui se consacre à l'administration de thérapies à base d'ARN. Elle développe des conjugués anticorps-oligonucléotides (AOC) conçus pour traiter des maladies jusqu'alors impossibles à traiter avec des thérapies à base d'ARN. Son principal produit candidat, l'AOC 1001, destiné au traitement de la dystrophie myotonique de type 1, une maladie musculaire monogénique rare, est en phase 1/2 d'essai clinique.

Avidity Biosciences, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Avidity Biosciences se comparent-ils à sa capitalisation boursière ?
RNA statistiques fondamentales
Capitalisation boursière	US$4.89b
Bénéfices(TTM)	-US$252.45m
Recettes(TTM)	US$10.60m

461.3x

Ratio P/S

-19.4x

Ratio P/E

Le site RNA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
RNA compte de résultat (TTM)
Recettes	US$10.60m
Coût des recettes	US$231.30m
Marge brute	-US$220.70m
Autres dépenses	US$31.75m
Les revenus	-US$252.45m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-2.16
Marge brute	-2,082.31%
Marge bénéficiaire nette	-2,381.82%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de RNA?

Voir les performances historiques et les comparaisons

RNA Aperçu des actions

Récompenses

Analyse des risques

Avidity Biosciences, Inc. Concurrents

NasdaqGS:RARE

US$5.4b

NasdaqGS:IMVT

US$4.3b

NasdaqGS:ISEE

US$5.5b

NasdaqGS:DNLI

US$4.4b

Historique des prix et performances

Nouvelles et mises à jour récentes

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Recent updates

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophin Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock